What's Happening?
Atossa Therapeutics has announced the publication of results from the KARISMA Endoxifen trial, which demonstrated significant reductions in mammographic breast density (MBD) in healthy premenopausal women. The trial, conducted in Sweden, involved 240
participants and showed that both 1 mg and 2 mg doses of Endoxifen significantly reduced MBD compared to placebo. The 1 mg dose was particularly notable for its tolerability, comparable to placebo, suggesting its potential as a breast cancer risk prevention therapy.
Why It's Important?
The findings from the KARISMA Endoxifen trial are significant as they offer a potential new approach to breast cancer prevention. Reducing MBD is crucial as it is a known risk factor for breast cancer. The trial's results suggest that Endoxifen could provide a more tolerable alternative to existing treatments like tamoxifen, which is often limited by side effects. This development could lead to broader acceptance and use of preventive therapies among women at elevated risk of breast cancer.
What's Next?
Atossa Therapeutics plans to further develop Endoxifen as a preventive therapy for breast cancer. Future studies will focus on confirming its efficacy in reducing breast cancer incidence among high-risk women. The company will also explore regulatory pathways to bring Endoxifen to market, potentially offering a new option for breast cancer prevention.
